Tuesday, 11 May 2021

Nearly 40% of AstraZeneca Investors Reject Boss’s Bonus Rise

THE GUARDIAN: Covid vaccine maker passes its remuneration policy but suffers sizeable rebellion

AstraZeneca has suffered a substantial shareholder rebellion over proposals to hand its chief executive, Pascal Soriot, bigger bonus awards for the second consecutive year.

Nearly 40% voted against the policy, which could hand him pay and perks of nearly £18m for 2021.

At the company’s annual meeting in Cambridge, the Anglo-Swedish drugmaker managed to win approval for its remuneration policy, which required support from shareholders holding more than 50% of the firm’s stock, but investors owning 39.8% of the shares opposed it. » | Julia Kolleweand Damien Gayle | Tuesday, May 11, 2021

Pascal Soriot »